Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer

Gedatolisib combinations double PFS vs alpelisib in PIK3CA-mutant advanced breast cancer

Sacituzumab govitecan plus pembrolizumab improves outcomes beyond progression in PD-L1-positive mTNBC

ASCO 2026: Highlights and analysis

GLP-1 therapy associated with reduced breast cancer risk

Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission

Weight loss intervention improves quality of life in breast cancer survivors

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard of care in triple-negative breast cancer

Omission of axillary lymph node dissection reduces arm morbidity without compromising survival in select breast cancer cases

ASCO 2026: Breast cancer overview

ctDNA positivity predicts poor response and recurrence risk in triple-negative breast cancer